Compare MBBC & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | CPHI |
|---|---|---|
| Founded | 1902 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 46.5M |
| IPO Year | 2020 | 2008 |
| Metric | MBBC | CPHI |
|---|---|---|
| Price | $15.23 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 495.9K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.22 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.25 | $0.38 |
| 52 Week High | $15.79 | $19.19 |
| Indicator | MBBC | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 45.97 |
| Support Level | $14.63 | $0.53 |
| Resistance Level | $15.77 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 93.94 | 11.65 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.